Skip to content
Tirzepatide, FDA approved medication for weight loss
November 9, 2023:
Update on FDA approval for Tirzepatide for weight loss.
A revolutionary weight loss medication, Tirzepatide, has received approval from the U.S. Food and Drug Administration (FDA), marking a significant milestone in the treatment of obesity. This novel medication has shown promising results in clinical trials, offering a new hope for millions of individuals struggling with weight management.
Tirzepatide, a once-weekly injectable medication, works by mimicking natural hormones that regulate appetite and food intake. Clinical studies have demonstrated its effectiveness in not only reducing body weight but also improving several health markers associated with obesity, including blood sugar levels and cardiovascular risk factors.
This approval follows a rigorous evaluation process where Tirzepatide’s safety and efficacy were thoroughly assessed. The clinical trials highlighted significant weight reduction in participants, with an acceptable safety profile. The medication is indicated for adults with obesity or overweight with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol.
Healthcare professionals are optimistic about the potential of Tirzepatide to transform the approach to weight management. This medication offers an alternative for individuals who have not achieved sufficient weight loss through diet and exercise alone.
Patients are advised to consult with their healthcare providers to understand if Tirzepatide is suitable for them and to discuss a comprehensive weight management plan that includes a healthy diet and physical activity.
It was announced in October of this year that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation of the FDA approval process for tirzepatide to treat adults with obesity, or overweight with weight-related comorbidities.
Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide is a single novel molecule that activates the body’s receptors for GIP and GLP-1, which are natural incretin hormones. GIP is a hormone that may complement the effects of GLP-1 receptor agonism. GIP has been shown to decrease food intake while blunting the metabolic adaptive responses that usually occur with calorie restriction resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids. Tirzepatide is in Phase 3 development for adults with obesity, or overweight with weight-related comorbidity.
How It WOrks:
GLP-1 and GIP are gut hormones called incretins, and the intestines release them when we eat. Incretins stimulate the secretion of insulin from the pancreas’ insulin-producing cells, which are called beta cells.
GLP-1 increases the release of insulin from the pancreas. It also reduces levels of glucagon, a hormone that prevents blood sugar from decreasing too much.
Another role of GLP-1 is increasing the number and volume of beta cells in the pancreas. It also promotes a feeling of fullness by delaying stomach emptying and controlling appetite in the brain.
Like GLP-1, GIP increases insulin release. It also improves beta cell production and decreases beta cell destruction. Additionally, GIP reduces fat accumulation, increases bone formation, increases glucagon production, and reduces acid secretion in the stomach.
When will it be FDA approved for weightloss?
While Tirzepatide is FDA-approved for treating diabetes right now, remember that it is on Fast Track Designation. Therefore, it will likely get full approval in 6 months (by summer of 2023) for weight loss in overweight/obese non-diabetic patients as we already have solid evidence of tackling the problem with GLP-1 receptor agonists.
Learn More About Peptides
CJC-1295 is a 30 amino acid peptide hormone that has shown promising and amazing results as a Growth Hormone Releasing Hormone (GHRH) analog. CJC-1295 stimulates HGH secretion and can provide a steady increase of HGH with minimal effect on cortisol and prolactin levels. This means increased protein synthesis thus promoting growth and fat loss simultaneously. Ipamorelin mimics ghrelin and binds to the ghrelin receptor (or GH secretagogue receptor, GHSR) inthe brain, thereby selectively stimulating the release of GH from the pituitary gland. This results in increased plasma GH levels, which would affect many biological processes. Unlike other GH releasing peptides, Ipamorelin only stimulates GH release in a manner very similar to that of growth hormone releasing hormone. This combination results in a great aid for sleep, energy, stamina and recovery benefits. Learn more…
BPC 157, composed of 15 amino acids, is a partial sequence of body protection compound (BPC) that is discovered in and isolated from human gastric juice. Experimentally it has been demonstrated to accelerate the healing of many different wounds, including tendons, muscles, nervous system and superior healing of damaged ligaments. Those who suffer from discomfort due to muscle sprains, tears and damage may benefit from treatment with this peptide. It can also help aid skin burns to heal at a faster rate and increase blood flow to damaged tissues. Learn more…
Sermorelin is a peptide analogue of growth hormone-releasing hormone (GHRH) which is used as a diagnostic agent to assess growth hormone (GH) secretion for the purpose of diagnosing growth hormone deficiency. It is a 29-amino acid polypeptide representing the 1–29 fragment from endogenous human GHRH, thought to be the shortest fully functional fragment of GHRH. Learn more…
Ibutamoren (MK-677) is a potent, long-acting, orally-active, selective, and non-peptide agonist of the ghrelin receptor and a growth hormone secretagogue, mimicking the growth hormone (GH)-stimulating action of the endogenous hormone ghrelin. It has been shown to increase the secretion of several hormones including GH and insulin-like growth factor 1 (IGF-1) and produces sustained increases in the plasma levels of these hormones without affecting cortisol levels. Learn more…
IGF-1 LR3 is a polypeptide long-chain amino acid peptide hormone. Insulin-like Growth Factor (IGF-1 Long-Arginine 3), an 83 amino acid analog of IGF-1, is a highly anabolic hormone released primarily in the liver with the stimulus of growth hormone (HGH). IGF-1 LR3 plays an important role in cell proliferation, cell-to-cell communication and cell division.IGF-1 LR3 is a derivative of IGF-1. Due to its structural adjustment, IGF-1 LR3 has a much longer half-life and results may persist in the bloodstream for up to 120 times longer. Learn more…
Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide is a single novel molecule that activates the body’s receptors for GIP and GLP-1, which are natural incretin hormones. GIP is a hormone that may complement the effects of GLP-1 receptor agonism. GIP has been shown to decrease food intake while blunting the metabolic adaptive responses that usually occur with calorie restriction resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids. Learn more…
Peptides are versatile compounds that offer a wide range of benefits, from enhancing skin health to promoting muscle growth and overall well-being. To find the best peptide for your specific needs, it’s crucial to start with a clear understanding of your goals. Learn more…
If you have any additional questions, please do not hesitate to reach out to our clinic.
It is important to have blood work performed prior to beginning this medication to assess liver and kidney function as well as assist in identifying any additional underlying health conditions.